|
6-deoxy-2-O-methyl-alpha-L-galactopyranose
|
DB04515 |
|
|
NV-07a
|
DB05845 |
[NV-07a is topical skin repair compound protecting skin from sun-induced immunosuppression and UV-induced damage.] |
|
2-Isobutyl-3-Methoxypyrazine
|
DB04512 |
|
|
N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide
|
DB04513 |
|
|
trans NV-04
|
DB05843 |
[trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.] |
|
AI-850
|
DB05842 |
[AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.] |
|
3-phospho-D-glyceric acid
|
DB04510 |
|
|
N-Succinyl Methionine
|
DB04511 |
|
|
AI-128
|
DB05841 |
[AI-128 is the first human demonstration of sustained release drug administration in the lung. AI-128 consists of slowly dissolving microspheres designed to control where drug particles go in the lung and how quickly they release their drug.] |
|
AGI-1096
|
DB05840 |
[AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic organ transplant rejection.] |
|
Desvancosaminyl vancomycin
|
DB04529 |
|
|
PI-166
|
DB05859 |
[PI-166 is a small organic compound with specific avidity to liver cancer cells. It has demonstrated the ability to reduce the growth of rat hepatomas, which is like human hepatomas, are resistant to established anti-cancer agents.] |
|
beta-Hydroxyasparagine
|
DB04527 |
|
|
2,4-Dinitrophenol
|
DB04528 |
[A toxic dye, chemically related to trinitrophenol (picric acid), used in biochemical studies of oxidative processes where it uncouples oxidative phosphorylation. It is also used as a metabolic stimulant. (Stedman, 26th ed)] |
|
BI-K0376
|
DB05858 |
[BI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.] |
|
Q-Derp1
|
DB05857 |
[Q-Derp1 is developed by Cytos Biotechnology as an immunodrug. It is an antigen for the prevention of various major chronic diseases. Derp1 is the dominant allergic protein found in dust mite feces.] |
|
2-(Carboxymethoxy)-5-[(2s)-2-({(2s)-2-[(3-Carboxypropanoyl)Amino] -3-Phenylpropanoyl}Amino)-3-Oxo-3-(Pentylamino)Propyl]Benzoic Acid
|
DB04525 |
|
|
L-Glycero-D-Manno-Heptopyranose
|
DB04526 |
|
|
CPD 923
|
DB05856 |
[CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.
] |
|
Rivanicline
|
DB05855 |
[Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a partial agonist at neuronal nicotinic acetylcholine receptors, binding primarily to the α4β2 subtype. It was originally developed as a potential treatment for Alzheimer's disease for its nootropic effects but has also been found to inhibit the production of Interleukin-8. It has subsequently been developed as a potential anti-inflammatory treatment for ulcerative colitis. Rivanicline also has stimulant and analgesic actions which are thought due to increased noradrenaline release.] |
